JNJ News 104.59 06/25/2014 05:07:11 Johnson & Johnson (JNJ)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 104.59 $JNJ

Arteriosclerosis - Pipeline Review, H1 2014
M2 - 52 mins ago
Research and Markets (http://www.researchandmarkets.com/research/64g45x/arteriosclerosis) has announced the addition of the "Arteriosclerosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AnGes MG - Angelini - CytoTools - ECI - Johnson & Johnson - Kowa Company - KunWha Pharmaceutical - LTT Bio-Pharma - Nippon Shinyaku For more information visit http://www.researchandmarkets.com/research/64...osclerosis

Final Glance: Pharmaceuticals companies
AP - Tue Jun 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Final Glance: Medical Devices companies
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:

Midday Glance: Pharmaceuticals companies
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Midday Glance: Medical Devices companies
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:

Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Early Glance: Medical Devices companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:

Avon's Calling, but Will Higher Profits Push Investors to Open the Door?
at The Street - Tue Jun 24, 8:45AM CDT
The beauty products company has undergone a makeover with revamped leadership, and Avon might add a new look to your portfolio.

Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research
PR Newswire - Tue Jun 24, 8:30AM CDT
Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Centre for Infection Research (HZI), Germany and The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.

Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute's Belfer Institute for Applied Cancer Science
PR Newswire - Tue Jun 24, 7:00AM CDT
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. today announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline.

Cost Controls vs. Curing Citizens: Fallout from the U.K.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Just like the protagonist in " Fortunately, Unfortunately " Gilead Sciences is experiencing a disproportionate amount of highs and lows. Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo...

FIFA World Cup: China Scores over Brazil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
China will earn significantly from the costliest FIFA World Cup tournament ever; that too without making massive investments.

Stryker Momentum Continues but M&A Activities Pose Threat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 1:50PM CDT
Investors are confident about Stryker Corporation (SYK) given its continued momentum based on its potential to become a medtech company.

Stock Market News for June 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 9:06AM CDT
Benchmarks closed Friday’s trading session with modest gains as optimism from Wednesday’s policy statement spilled over into a second successive day

The Zacks Analyst Blog Highlights: Intel, Boeing, Chevron, Johnson & Johnson and Vertex Pharmaceuticals
PR Newswire - Mon Jun 23, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Intel Corporation (Nasdaq:INTC-Free Report), Boeing Co. (NYSE:BA-Free Report), Chevron Corp. (NYSE:CVX-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report) and Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report).

Johnson & Johnson Has Returned 16.4% Since SmarTrend Recommendation (JNJ)
Comtex SmarTrend(R) - Fri Jun 20, 5:07PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 4 months, Johnson & Johnson has returned 16.40% as of today's recent price of $105.27.

Tetraphase Progresses with Eravacycline Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 4:20PM CDT
Tetraphase Pharmaceuticals (TTPH) announced the completion of patient enrolment for the phase III IGNITE 2 study on eravacycline.

SmarTrend Watching for Potential Pullback in Shares of Johnson & Johnson After 1.41% Gain
Comtex SmarTrend(R) - Fri Jun 20, 3:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $104.07 to a high of $105.48. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $103.87 on volume of 12.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Insiders Buy Up on MicroStrategy While Analysts Expect Growth

Updated Category News Views 198

Insider Purchases Indicate Confidence in MicroStrategy Recently, insiders at MicroStrategy Incorporated (NASDAQ: MSTR) have made notable stock purchases that are turning heads in the financial community. Even though there were increases in insider share sales in the last quarter, which reached a two-year peak, the market has not reacted unfavorably. Most of these sales...

Continue Reading
Burlington Stores Insider Transaction: Stephen Ferroni's Move

Updated Category News Views 174

Burlington Stores Insider Transaction Details In a significant move recently disclosed in an SEC filing, Stephen Ferroni, the Senior Vice President at Burlington Stores, made headlines by exercising company stock options. This transaction, involving the exercise of options for 1,123 shares, amounted to a transaction value of approximately $200,331. The filing highlights...

Continue Reading
Clairvest Group's Strategic Acquisition of MGM Northfield Park

Updated Category News Views 371

Clairvest Group Expands Horizons with MGM Northfield Park Acquisition Exciting developments are shaping the landscape for Clairvest Group Inc. as they embark on a significant acquisition journey with MGM Northfield Park. This strategic move not only highlights Clairvest's commitment to growth in the gaming sector but also enhances their longstanding reputation for...

Continue Reading
Innovent Biologics Showcases Promising Research at ADA 85th Sessions

Updated Category News Views 576

Innovent Biologics Presents Cutting-Edge Research at ADA Innovent Biologics, Inc. (HKEX: 01801) has made significant advancements in the biopharmaceutical industry, focusing on innovative treatments for oncology, autoimmune diseases, and metabolic conditions. Recently, the company announced that it will showcase exciting results from its research pipeline at the American...

Continue Reading
Promising Results from HERIZON-GEA-01 Trial Support Ziihera®

Updated Category News Views 288

Encouraging HERIZON-GEA-01 Phase 3 Findings Reinforce Ziihera®’s Role Ziihera, when combined with chemotherapy, has demonstrated a significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy combinations. It also showed a strong trend towards enhancing overall survival (OS) at the first analysis. Clinical Outcomes of Ziihera in...

Continue Reading